{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:55:05Z","timestamp":1792518905434,"version":"4.5.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2021,10,1]]},"DOI":"10.1001\/jamadermatol.2021.3154","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T15:33:13Z","timestamp":1629905593000},"page":"1182","source":"Crossref","is-referenced-by-count":73,"title":["Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis"],"prefix":"10.1001","volume":"157","author":[{"given":"Khalaf","family":"Kridin","sequence":"first","affiliation":[{"name":"L\u00fcbeck Institute of Experimental Dermatology, University of L\u00fcbeck, L\u00fcbeck, Germany"},{"name":"Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Charlotte","family":"Br\u00fcggen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Zurich, Zurich, Switzerland"},{"name":"Medical Campus Davos, Davos, Switzerland"},{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ser-Ling","family":"Chua","sequence":"additional","affiliation":[{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France"},{"name":"Department of Dermatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Bygum","sequence":"additional","affiliation":[{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France"},{"name":"Department of Dermatology and Allergy Center, Odense University Hospital, Clinical Institute, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Walsh","sequence":"additional","affiliation":[{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France"},{"name":"Department of Dermatology, King\u2019s College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam C.","family":"N\u00e4geli","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesta","family":"Kucinskiene","sequence":"additional","affiliation":[{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France"},{"name":"Department of Skin and Venereal Diseases, Lithuanian University of Health Sciences (LUHS), Hospital of LUHS Kauno Klinikos, European Reference Network for Rare and Complex Diseases of the Skin members, Kaunas, Lithuania"},{"name":"Department of Skin and Venereal Diseases, Lithuanian University of Health Sciences, Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"French","sequence":"additional","affiliation":[{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France"},{"name":"Department of Dermatology, University Hospital, Munich University of Ludwig Maximilian, Munich, Germany"},{"name":"Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"T\u00e9tart","sequence":"additional","affiliation":[{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France"},{"name":"Toxic Bullous Dermatoses and Severe Drug Reactions reference center, TOXIBUL FIMARAD network, Assistance Publique-H\u00f4pitaux de Paris, Henri Mondor Hospital, Cr\u00e9teil, France"},{"name":"Department of Dermatology, Inserm U519, Rouen University Hospital, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Didona","sequence":"additional","affiliation":[{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France"},{"name":"Rare Disease Unit, I Dermatology Division, Istituto Dermopatico dell\u2019Immacolata, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Milpied","sequence":"additional","affiliation":[{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France"},{"name":"Toxic Bullous Dermatoses and Severe Drug Reactions reference center, TOXIBUL FIMARAD network, Assistance Publique-H\u00f4pitaux de Paris, Henri Mondor Hospital, Cr\u00e9teil, France"},{"name":"Department of Dermatology, Saint Andr\u00e9 Hospital, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamari","family":"Ranki","sequence":"additional","affiliation":[{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France"},{"name":"Department of Dermatology, Allergology and Venereology, University of Helsinki, Helsinki, Finland"},{"name":"Helsinki University Hospital, Inflammation Center, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Salavastru","sequence":"additional","affiliation":[{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France"},{"name":"Carol Davila University of Medicine and Pharmacy, Bucharest, Romania"},{"name":"Department of Pediatric Dermatology, Colentina Clinical Hospital, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"B\u0159ezinov\u00e1","sequence":"additional","affiliation":[{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France"},{"name":"First Department of Dermatovenereology, Masaryk University Faculty of Medicine, St Ann\u2019s Faculty Hospital in Brno, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna","family":"Divani-Patel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"Lorentzen","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Center, Odense University Hospital, Clinical Institute, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Loft","family":"Nagel","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Center, Odense University Hospital, Clinical Institute, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skaidra","family":"Valiukeviciene","sequence":"additional","affiliation":[{"name":"Department of Skin and Venereal Diseases, Lithuanian University of Health Sciences (LUHS), Hospital of LUHS Kauno Klinikos, European Reference Network for Rare and Complex Diseases of the Skin members, Kaunas, Lithuania"},{"name":"Department of Skin and Venereal Diseases, Lithuanian University of Health Sciences, Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktorija","family":"Karpavi\u010di\u016bt\u0117","sequence":"additional","affiliation":[{"name":"Department of Skin and Venereal Diseases, Lithuanian University of Health Sciences, Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George-Sorin","family":"Tiplica","sequence":"additional","affiliation":[{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France"},{"name":"Carol Davila University of Medicine and Pharmacy, Bucharest, Romania"},{"name":"Department of Dermatology, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Oppel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Munich University of Ludwig Maximilian, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Oschmann","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Munich University of Ludwig Maximilian, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"de Prost","sequence":"additional","affiliation":[{"name":"Toxic Bullous Dermatoses and Severe Drug Reactions reference center, TOXIBUL FIMARAD network, Assistance Publique-H\u00f4pitaux de Paris, Henri Mondor Hospital, Cr\u00e9teil, France"},{"name":"Intensive care unit, AP-HP, Henri Mondor Hospital, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem","family":"Vorobyev","sequence":"additional","affiliation":[{"name":"L\u00fcbeck Institute of Experimental Dermatology, University of L\u00fcbeck, L\u00fcbeck, Germany"},{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France"},{"name":"Department of Dermatology, University Medical Center Schleswig-Holstein, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Ingen-Housz-Oro","sequence":"additional","affiliation":[{"name":"ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France"},{"name":"Toxic Bullous Dermatoses and Severe Drug Reactions reference center, TOXIBUL FIMARAD network, Assistance Publique-H\u00f4pitaux de Paris, Henri Mondor Hospital, Cr\u00e9teil, France"},{"name":"Dermatology Department, AP-HP, Henri Mondor Hospital, Cr\u00e9teil, France"},{"name":"University Paris-Est Cr\u00e9teil EpiDermE, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10106","key":"doi210045r1","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","article-title":"Severe cutaneous adverse reactions to drugs.","volume":"390","author":"Duong","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"doi210045r2","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1111\/jdv.v34.9","article-title":"Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN).","volume":"34","author":"Kuijper","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"doi210045r3","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults.","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi210045r4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/bjd.v182.3","article-title":"Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome\/toxic epidermal necrolysis) in France during 2003-2016: a four-source capture-recapture estimate.","volume":"182","author":"Chaby","year":"2020","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi210045r5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"issue":"4","key":"doi210045r6","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamadermatol.2018.5605","article-title":"Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis\u2014ABCD-10.","volume":"155","author":"Noe","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"3","key":"doi210045r7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"issue":"1","key":"doi210045r8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/bjd.2019.181.issue-1","article-title":"British Association of Dermatologists\u2019 guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in children and young people, 2018.","volume":"181","author":"McPherson","year":"2019","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi210045r9","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/bjd.2016.174.issue-6","article-title":"U.K. guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016.","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi210045r10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13023-018-0793-7","article-title":"Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins).","volume":"13","author":"Ingen-Housz-Oro","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"doi210045r11","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis.","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi210045r12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2020.08.122","article-title":"Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis.","volume":"84","author":"Tsai","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"20","key":"doi210045r13","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"doi210045r14","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jaip.2019.09.032","article-title":"Searching for the culprit drugs for Stevens-Johnson syndrome and toxic epidermal necrolysis from a nationwide claim database in Korea.","volume":"8","author":"Yang","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"doi210045r15","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States.","volume":"138","author":"Micheletti","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"1","key":"doi210045r16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs: the EuroSCAR-study.","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"4","key":"doi210045r17","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx232","article-title":"Sulfamethoxazole-trimethoprim (cotrimoxazole) for skin and soft tissue infections including impetigo, cellulitis, and abscess.","volume":"4","author":"Bowen","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"doi210045r18","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1111\/jdv.v35.2","article-title":"Carrying out local care for epidermal necrolysis: survey of practices.","volume":"35","author":"Ingen-Housz-Oro","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi210045r19","first-page":"247","article-title":"Trends in mortality rates for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): experience of a single center in France between 1997 and 2017.","volume":"182","author":"Bettuzzi","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi210045r20","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jaad.2020.02.066","article-title":"Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults.","volume":"82","author":"Seminario-Vidal","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi210045r21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression.","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"issue":"6","key":"doi210045r22","first-page":"743","article-title":"High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases.","volume":"20","author":"Chen","year":"2010","journal-title":"Eur J Dermatol"},{"issue":"3","key":"doi210045r23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1060028014560012","article-title":"Corticosteroids in Stevens-Johnson syndrome\/toxic epidermal necrolysis: current evidence and implications for future research.","volume":"49","author":"Law","year":"2015","journal-title":"Ann Pharmacother"},{"issue":"3","key":"doi210045r24","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-a antagonist in CTL-mediated severe cutaneous adverse reactions.","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"issue":"5","key":"doi210045r25","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1684\/ejd.2020.3883","article-title":"A new case series on etanercept treatment for toxic epidermal necrolysis.","volume":"30","author":"Paradisi","year":"2020","journal-title":"Eur J Dermatol"},{"issue":"1","key":"doi210045r26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/09546634.2019.1577548","article-title":"Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review.","volume":"31","author":"Zhang","year":"2020","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"doi210045r27","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi210045r28","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jid.2017.12.034","article-title":"Cyclosporine for epidermal necrolysis: absence of beneficial effect in a retrospective cohort of 174 patients-exposed\/unexposed and propensity score-matched analyses.","volume":"138","author":"Poizeau","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"10","key":"doi210045r29","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1016\/j.jid.2017.05.022","article-title":"Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches.","volume":"137","author":"Gonz\u00e1lez-Herrada","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"5","key":"doi210045r30","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi210045r31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/pds.3937","article-title":"Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry.","volume":"25","author":"Diphoorn","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"doi210045r32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/MD.0b013e3181ca4290","article-title":"Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures.","volume":"89","author":"de Prost","year":"2010","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"doi210045r33","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/CCM.0b013e31829eb94f","article-title":"Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation.","volume":"42","author":"de Prost","year":"2014","journal-title":"Crit Care Med"},{"issue":"5","key":"doi210045r34","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1111\/bjd.14934","article-title":"Renal replacement therapy during Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective observational study of 238 patients.","volume":"176","author":"Papo","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi210045r35","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jaip.2018.05.024","article-title":"A retrospective cohort study of the management and outcomes of children hospitalized with Stevens-Johnson syndrome or toxic epidermal necrolysis.","volume":"7","author":"Antoon","year":"2019","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2783034\/jamadermatology_kridin_2021_oi_210045_1634154542.6481.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:41:26Z","timestamp":1634776886000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2783034"}},"subtitle":["Insights From a Pan-European Multicenter Study"],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.3154","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,1]]}}}